These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25964967)

  • 1. Common stem--lutamide.
    Prescrire Int; 2014 Oct; 23(153):236. PubMed ID: 25964967
    [No Abstract]   [Full Text] [Related]  

  • 2. [New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
    Brasso K; Thomsen FB; Berg KD; Røder MA; Iversen P
    Ugeskr Laeger; 2013 Sep; 175(40):2328-32. PubMed ID: 24079321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Splicing variant of androgen receptors (AR-V7): New paradigms].
    Penel N
    Bull Cancer; 2016 Sep; 103(9):711-3. PubMed ID: 27591905
    [No Abstract]   [Full Text] [Related]  

  • 4. [Management of enzalutamide, a new hormonal therapy].
    Beuzeboc P; Benderra MA; de La Motte Rouge T
    Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [When to begin with androgen deprivation?].
    Bex A; Rübben H
    Urologe A; 1998 Mar; 37(2):133-4. PubMed ID: 9563119
    [No Abstract]   [Full Text] [Related]  

  • 6. Limiting the adverse effects of androgen suppression.
    Prescrire Int; 2013 Jan; 22(134):21. PubMed ID: 23367680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment for advanced prostate cancer.
    FDA Consum; 2004; 38(2):4. PubMed ID: 15101352
    [No Abstract]   [Full Text] [Related]  

  • 8. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer drugs. Making sense of the options.
    Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzalutamide for the treatment of castration-resistant prostate cancer.
    Ha YS; Goodin S; DiPaola RS; Kim IY
    Drugs Today (Barc); 2013 Jan; 49(1):7-13. PubMed ID: 23362491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide (Xtandi) for prostate cancer.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
    Zgliczyński S; Borówka A
    Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 14. New indication sought for bicalutamide.
    Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Caubet JF
    J Natl Cancer Inst; 1999 Feb; 91(4):381-2. PubMed ID: 10050874
    [No Abstract]   [Full Text] [Related]  

  • 19. The evolution of antiandrogens: MDV3100 comes of age.
    Dumas L; Payne H; Chowdhury S
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):131-3. PubMed ID: 22316360
    [No Abstract]   [Full Text] [Related]  

  • 20. Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
    Spratt DE; Tward JD
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):899-902. PubMed ID: 32928598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.